Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
AssigneeNovartis AG
InventorsShephard MPOFU, Hanno RICHARDS, Gregory LIGOZIO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using IL-17 antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.
Claims21
-28. (canceled)
A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), comprising selectively administering to the patient about 150 mg-about 300 mg of an 1L-17 antibody by subcutaneous injection with initial dosing at week 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, wherein the patient is selected for treatment based on having had an inadequate response to previous treatment with a TNF alpha antagonist, and wherein:
- i) the IL-17 antibody comprises an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
- ii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
- iii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
- iv) the 1L-17 antibody comprises an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15;
- or
- v) the IL-17 antibody is secukinumab.
A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), comprising selectively administering to the patient about 150 mg-about 300 mg of an IL-17 antibody by subcutaneous injection with initial dosing at week 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, wherein the patient is selected for treatment based on having concomitant psoriasis, and wherein:
- i) the IL-17 antibody comprises an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
- ii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
- iii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
- iv) the IL-17 antibody comprises an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15;
- or
- v) the IL-17 antibody is secukinumab.
A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), comprising selectively administering to the patient about 150 mg-about 300 mg of an IL-17 antibody by subcutaneous injection with initial dosing at week 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, wherein the patient is selected for treatment based on being TNF nïave and not having concomitant psoriasis, and wherein:
- i) the IL-17 antibody comprises an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
- ii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
- iii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
- iv) the IL-17 antibody comprises an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15;
- or
- v) the IL-17 antibody is secukinumab.
A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), administering the patient about 150 mg-about 300 mg of secukinumab by subcutaneous injection every 4 weeks.
Dependencies are inferred from the claim text.